COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
Las Vega (Nevada), United States //— “Hereditary Angioedema Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Hereditary Angioedema Market.
The Hereditary Angioedema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working on 30+ drugs in the Hereditary Angioedema therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Hereditary Angioedema Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Hereditary Angioedema and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hereditary Angioedema Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Hereditary Angioedema market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Companies are focusing on executing a successful launch that meets the urgent demand for a once-daily oral therapy that will allow Hereditary Angioedema patients to live a more normal life. An orally delivered, small molecule offers the opportunity to improve treatment for the disease by making it more convenient for patients to take therapies.
Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Route of Administration
Hereditary angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
– Infusion
– Intradermal
– Intramuscular
– Intranasal
– Intravenous
– Oral
– Parenteral
– Subcutaneous
– Topical
Molecule Types of the Emerging Therapies:
Products have been categorized under various Molecule types, such as
– Gene therapies
– Small molecule
– Vaccines
– Polymers
– Peptides
– Monoclonal antibodies
Hereditary Angioedema Therapeutics Landscape
There are approx. 20+ key companies developing therapies for Hereditary angioedema. Currently, KalVista Pharmaceuticals is leading the therapeutics market with its Hereditary angioedema drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Hereditary Angioedema Therapeutics Market include:
– BioCryst Pharmaceuticals
– KalVista Pharmaceuticals
– Pharvaris
– BioMarin Pharmaceutical
– Ionis Pharmaceuticals, Inc.
– Intellia Therapeutics
And many others
Hereditary Angioedema Therapies covered in the report include:
– KVD900: KalVista Pharmaceuticals
– PHA121: Pharvaris
– BMN 331: BioMarin Pharmaceutical
– IONIS-PKK-LRx: Ionis Pharmaceuticals
– CSL312: CSL Behring
– NTLA-2002: Intellia Therapeutics
– PHA-022121: Pharvaris Netherlands B.V
And many more
Explore More About the Emerging Drugs and Key Companies: Hereditary Angioedema Pipeline Development Activities
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Hereditary Angioedema Current Treatment Patterns
4. Hereditary Angioedema – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Hereditary Angioedema Late-Stage Products (Phase-III)
7. Hereditary Angioedema Mid-Stage Products (Phase-II)
8. Hereditary Angioedema Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hereditary Angioedema Discontinued Products
13. Hereditary Angioedema Product Profiles
14. Key Companies in the Hereditary Angioedema Market
15. Key Products in the Hereditary Angioedema Therapeutics Segment
16. Dormant and Discontinued Products
17. Hereditary Angioedema Unmet Needs
18. Hereditary Angioedema Future Perspectives
19. Hereditary Angioedema Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Hereditary Angioedema Therapeutic Outlook
Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.